Xeris Biopharma Holdings, Inc. (XERS)
XERS Stock Price Chart
Explore Xeris Biopharma Holdings, Inc. interactive price chart. Choose custom timeframes to analyze XERS price movements and trends.
XERS Company Profile
Discover essential business fundamentals and corporate details for Xeris Biopharma Holdings, Inc. (XERS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2018
Employees
394.00
Website
https://www.xerispharma.comCEO
John P. Shannon
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS Financial Timeline
Browse a chronological timeline of Xeris Biopharma Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is $0.01.
Earnings released on 7 Aug 2025
EPS came in at -$0.01 surpassing the estimated -$0.03 by +66.67%, while revenue for the quarter reached $71.54M , missing expectations by -0.98%.
Earnings released on 8 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $60.12M , beating expectations by +4.36%.
Earnings released on 6 Mar 2025
EPS came in at -$0.03 surpassing the estimated -$0.08 by +62.50%, while revenue for the quarter reached $60.10M , beating expectations by +9.47%.
Earnings released on 8 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $54.27M , beating expectations by +5.52%.
Earnings released on 8 Aug 2024
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $48.07M , beating expectations by +4.92%.
Earnings released on 9 May 2024
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%, while revenue for the quarter reached $40.64M , missing expectations by -2.81%.
Earnings released on 6 Mar 2024
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $44.39M , missing expectations by -3.10%.
Earnings released on 9 Nov 2023
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $48.32M , beating expectations by +13.16%.
Earnings released on 8 Aug 2023
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%, while revenue for the quarter reached $38.01M , beating expectations by +8.11%.
Earnings released on 9 May 2023
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached $33.20M , beating expectations by +6.97%.
Earnings released on 8 Mar 2023
EPS came in at -$0.10 surpassing the estimated -$0.16 by +37.50%, while revenue for the quarter reached $33.14M , beating expectations by +7.04%.
Earnings released on 9 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $29.73M , beating expectations by +2.35%.
Earnings released on 10 Aug 2022
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%, while revenue for the quarter reached $25.31M , missing expectations by -38.40%.
Earnings released on 11 May 2022
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%, while revenue for the quarter reached $22.07M , missing expectations by -5.64%.
Earnings released on 10 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.21 by -100.00%, while revenue for the quarter reached $21.43M , beating expectations by +12.94%.
Earnings released on 10 Nov 2021
EPS came in at -$0.36 surpassing the estimated -$0.37 by +2.70%, while revenue for the quarter reached $11.04M , beating expectations by +0.23%.
Earnings released on 5 Aug 2021
EPS came in at -$0.41 falling short of the estimated -$0.31 by -32.26%, while revenue for the quarter reached $8.91M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$0.30 surpassing the estimated -$0.31 by +3.23%, while revenue for the quarter reached $8.05M , missing expectations by -10.53%.
Earnings released on 9 Mar 2021
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%, while revenue for the quarter reached $7.09M .
Earnings released on 9 Nov 2020
EPS came in at -$0.35 surpassing the estimated -$0.54 by +35.19%, while revenue for the quarter reached $9.45M , missing expectations by -24.64%.
XERS Stock Performance
Access detailed XERS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.